It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...
On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...